$594 Million is the total value of VR Adviser, LLC's 28 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 62.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVTE | Sell | AEROVATE THERAPEUTICS INC | $21,912,562 | +58.5% | 747,869 | -10.3% | 3.69% | +73.0% |
| MIST | Sell | MILESTONE PHARMACEUTICALS IN | $8,746,896 | -60.8% | 2,208,812 | -8.9% | 1.47% | -57.2% |
| Sell | LIANBIOsponsored ads | $7,860,597 | -26.9% | 4,793,047 | -10.9% | 1.32% | -20.2% | |
| Sell | MARINUS PHARMACEUTICALS INC | $7,047,406 | -66.4% | 1,770,705 | -43.9% | 1.19% | -63.4% | |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $3,256,533 | -66.5% | 447,326 | -62.7% | 0.55% | -63.4% |
| LIFE | Sell | ATYR PHARMA INC | $2,565,445 | -38.9% | 1,171,436 | -16.3% | 0.43% | -33.3% |
| CLDX | Exit | Celldex Therapeutics Inc | $0 | – | -75,000 | -100.0% | -0.32% | – |
| IMCR | Exit | Immunocore Holdings PLCads | $0 | – | -94,605 | -100.0% | -0.68% | – |
| ALT | Exit | Altimmune Inc | $0 | – | -369,306 | -100.0% | -0.73% | – |
| RXDX | Exit | Prometheus Biosciences Inc | $0 | – | -121,663 | -100.0% | -1.11% | – |
| Exit | Ventyx Biosciences Inc | $0 | – | -207,925 | -100.0% | -1.12% | – | |
| AKUS | Exit | Akouos Inc | $0 | – | -2,800,566 | -100.0% | -2.92% | – |
| TIL | Exit | Instil Bio Inc | $0 | – | -4,105,779 | -100.0% | -3.07% | – |
| GOSS | Exit | Gossamer Bio Inc | $0 | – | -1,747,000 | -100.0% | -3.23% | – |
| RLMD | Exit | Relmada Therapeutics Inc | $0 | – | -1,518,056 | -100.0% | -8.67% | – |
| TCDA | Exit | Tricida Inc | $0 | – | -9,050,064 | -100.0% | -14.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.